Pharmaceutical heavyweight Mylan, the latest poster child for drug-industry greed, finally stuck up for itself Thursday. It argued that “the system,” not avarice, was to blame for the company jacking up the price of EpiPens, a common (and life-saving ...
Dear EpiPen Customers . . .
Wall Street Journal
Painted as EpiPen Villain, Mylan's Chief Says She's No Such Thing
New York Times